SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets quarterly results sparked a sharp selloff as traders focused on the earnings shortfall, heavy AI infrastructure spending, negative free cash flow and concerns that AI search could pressure advertising; rapid Google Cloud growth offered a counterpoint. The community is split between viewing the drop as a buying opportunity and worrying that rising costs and search disruption may weigh on returns.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances positive Phase 2 lifileucel data in previously treated metastatic non-small cell lung cancer, and a scheduled webcast to discuss the results, are driving attention. Traders are largely enthusiastic and speculate about short covering, though claims of a data leak and predictions of a major rally are unconfirmed.

Alphabet Inc - Ordinary Shares - Class C

Alphabets earnings miss and heavy AI infrastructure spending, which pushed free cash flow negative, drove a sharp selloff despite strong Google Cloud growth. Traders are split between calling the drop an overreaction and buying the dip on cloud and AI demand, versus worrying that rising costs and slower Search growth may not deliver adequate returns.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts quarterly results topped expectations, with accelerating Azure growth and strong cloud demand tied to AI driving an initial after-hours rally. Traders welcomed the beat and outlook but debated whether the gains would hold, weighing cloud momentum against continued scrutiny of AI spending and cash flow.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNows mixed quarterly resultsan earnings miss and softer forward contract-growth guidance despite revenue growth and a higher AI outlooksparked a sharp selloff. Traders are split between viewing the decline as an overreaction to a small miss and worrying that slowing growth, high valuation, and AI disruption threaten the software business.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Reports circulating among traders that Marvell is in advanced talks to acquire Lumentum have driven attention, but no deal is confirmed and some traders question the rumors credibility and whether Marvell could finance it. Bulls are anticipating a takeover premium, while skeptics warn of dilution and debt for Marvell and expect Lumentums sharp move could reverse.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Reports of advanced talks for Marvell to acquire Lumentum have driven discussion, though traders stress the reports are unverified and say no public deal has been confirmed. The reaction is divided: some see strategic value in AI data-center optics, while others worry the deal could require substantial debt or share dilution and weigh on MRVL.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Vikings Q3 update and conference call drew attention to VK2735s advancing Phase 3 program, but managements indication that commercialization remains years away and the lack of clarity on partnering versus launching independently weighed on sentiment. Traders debated whether the cash raised can fund development without further dilution, while bullish holders pointed to positive maintenance data and the obesity-drug pipelines potential.

Fortinet, Inc. provides cybersecurity solutions to a variety of businesses, such as enterprises, communication service providers, government organizations, and small to medium-sized businesses. Its product portfolio includes network security, secure access service edge, enterprise networking, security operations, application security, and operational technology. The company was founded by Ken Xie and Michael Xie in November 2000 and is headquartered in Sunnyvale, CA.

Fortinet Inc

Fortinets earnings report is driving a sharp selloff: traders point to a lowered service-revenue outlook and signs of slowing growth, despite a headline beat and higher overall guidance. The community is split between calling the drop an overreaction and seeing it as a valuation reset, with some buyers eyeing the dip and others expecting further weakness.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotles mixed third-quarter results are driving attention: comparable sales growth exceeded expectations, but earnings missed and restaurant margins narrowed, while the company kept its low-single-digit sales-growth outlook. Traders are split between viewing the sales momentum and store expansion as encouraging and worrying that cost pressure and weak growth will weigh on profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

SystImmune, Inc. (SystImmune), a clinical stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that SystImmunes parent company Sichuan Biokin Pharmaceutical, Ltd. (Biokin) reported positive results from a prespecified interim analysis in the randomized, multicenter...

Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026

Bristol Myers Squibb (NYSE: BMY) today announced disclosure of interim safety and efficacy results from the multiple sclerosis (MS) cohorts of the Phase 1, single-arm, dose-escalation Breakfree-2 study evaluating zolacabtagene autoleucel (zola-cel; BMS-986353), an investigational, autologous...

Tempus Expands Strategic Collaboration with Bristol Myers Squibb

Tempus AI, Inc. (NASDAQ: TEM, Tempus) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, BMS), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and...

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimers Disease and Other Neurological Conditions

Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE: BMY, BMS) and Tempus AI, Inc. (NASDAQ: TEM, Tempus) to build a specialized, curated dataset and agentic AI capabilities...

Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study

SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that SystImmunes parent company Sichuan Biokin Pharmaceutical, Ltd. (Biokin) reported positive results from a prespecified interim analysis of the randomized Phase 3...

Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026

Bristol Myers Squibb (NYSE: BMY) today announced it will present new data from its oncology portfolio and pipeline across a broad range of solid tumors at the European Society for Medical Oncology (ESMO) 2026 Congress to be held October 23-27 in Madrid, Spain. Across 12 oral presentations and...

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBios Radiopharmaceutical Therapy, in Patients with GEP-NETs

Bristol Myers Squibb (NYSE: BMY) today announced positive topline results from the planned interim analysis of the ACTION-1 trial (NCT05477576) conducted by RayzeBio, Inc., a Bristol Myers Squibb company. The study met the primary endpoint with a statistically significant and clinically meaningful...

Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

Bristol Myers Squibb (NYSE: BMY) today announced topline results from the pivotal Phase 3 ALOFT-IPF trial evaluating the efficacy, safety and tolerability of admilparant, a potential first-in-class, orally administered, potent and selective lysophosphatidic acid receptor 1 (LPA1) antagonist, in...

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3 EXCALIBER-RRMM Study Bristol Myers Squibb (NYSE: BMY) today...

Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale

Key PointsJohnson & Johnson generates consistently higher quarterly revenue than Bristol-Myers Squibb, maintaining a clear lead in total dollars over the entire observed eight-quarter period without any interruption...

Bearish Sentiment

Yes, the bottom is in

No, more downside ahead

Too early to tell

Depends on the stock

Neocloud stocks like $NBIS, $CRWV, $IREN, and $APLD are rebounding after a brutal October. Have they bottomed?

Feed

News

Sentiment

Fundamentals

Info

CELG Celgene Corporation

Latest CELG News